Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2016

Feb 26, 2016

30291_dirs_2016-02-26_8dd94106-0af1-4872-b07c-9d24696df855.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2016-02-25

Reporting Person: Sandrock Alfred (EVP CMO Neuro & Neurodegenerat)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-02-25 Common Stock S 183 $261.90 Disposed 7990 Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.